irst-line inavolisib/placebo + palbociclib + fulvestrant (Inavo/Pbo+Palbo+Fulv) in patients (pts) with PIK3CA-mutated, hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer who relapsed during/within 12 months (mo) of adjuvant endocrine therapy completion: INAVO120 Phase III randomized trial additional analyses Meeting Abstract
| Authors: | Juric, D.; Kalinsky, K.; Turner, N. C.; Jhaveri, K. L.; Schmid, P.; Loi, S.; Saura, C.; Im, S. A.; Sunpaweravong, P.; Li, H.; Musolino, A.; Zhang, Q.; Nowecki, Z.; Leung, R. C. Y.; Thanopoulou, E.; Shankar, N.; Lei, G.; Devine, J.; Stout, T. J.; Loibl, S. |
| Abstract Title: | irst-line inavolisib/placebo + palbociclib + fulvestrant (Inavo/Pbo+Palbo+Fulv) in patients (pts) with PIK3CA-mutated, hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer who relapsed during/within 12 months (mo) of adjuvant endocrine therapy completion: INAVO120 Phase III randomized trial additional analyses |
| Meeting Title: | 2024 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 42 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2024 May 31-Jun 4 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2024-06-01 |
| Language: | English |
| ACCESSION: | WOS:001275557400114 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2024.42.16_suppl.1003 |
| Notes: | Meeting Abstract: 1003 -- Source: Wos |
